entity

ABCA7 with biomarker-guided dosing

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about ABCA7 with biomarker-guided dosing: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

1Connections
1Hypotheses
1Analyses
1Outgoing
0Incoming

Outgoing (1)

TargetRelationTypeStr
neurodegenerationpromoted: CSF Biomarker-Guided ABCA7 Therapeutic Dosingdisease0.62

Incoming (0)

SourceRelationTypeStr
No incoming edges

Targeting Hypotheses (1)

Hypotheses where this entity is a therapeutic target

HypothesisScoreDiseaseAnalysis
CSF Biomarker-Guided ABCA7 Therapeutic Dosing 0.619 neurodegeneration Why does the V1613M variant reduce amylo

Mentioning Analyses (1)

Scientific analyses that reference this entity

Why does the V1613M variant reduce amyloid pathology when ABCA7 loss-of-function

neurodegeneration | 2026-04-14 | 2 hypotheses Top: 0.619

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMIDAuthorsJournalYearCitations
No papers found